Novartis Signs a $7.8 Billion Chinese mRNA Deal

Novartis will pay $575 million upfront, and up to $7.8 billion in all, for a Suzhou mRNA autoimmune drug. The October 2, 2026 license with Abogen Biosciences is the largest in a run of China deals as Western patents near expiry.

Chinese biotech firms now originate about a third of the new molecules sitting in global pipelines. U.S. security rules still treat parts of that industry as a problem to contain.

Novartis Pays $575 Million for Abogen’s mRNA Therapy

Abogen, a clinical-stage group in Suzhou, said Novartis takes an exclusive worldwide license to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager meant to reset B cells in autoimmune disease. The Swiss firm also gets exclusive options on other programs built on Abogen’s RNA platform.

Abogen will receive an upfront payment of $575 million. If every option is exercised and agreed targets are met, it can earn about $7.2 billion more in development, regulatory and commercial milestones, plus royalties on future sales. The pact still needs customary closing conditions, including regulatory clearances.

ABO2203 uses mRNA so the patient’s body makes the T-cell engager itself. Abogen says that in-body production could lower the risk of cytokine release, a known hazard of injected T-cell engagers. Chief executive Bo Ying called it the first mRNA-encoded T-cell engager to enter clinical testing for autoimmune disease, and a step beyond the firm’s vaccine work, which includes a shingles shot in Phase 3 in China.

Achieving effective and durable immune reset remains an important goal across a number of autoimmune diseases. mRNA-encoded T-cell engagers represent an innovative approach that could complement existing therapeutic modalities by enabling in vivo production of these molecules.

Fiona Marshall, President of Biomedical Research, Novartis, Abogen announcement

The check arrives after late-stage trial setbacks in September put pressure on Novartis shares and on the firm’s ability to replace products as patents run down. Buying a platform option from Suzhou, rather than waiting on the next internal readout, is a verdict on where new mechanisms are coming from.

Three Checks in Two Weeks

Abogen is not an isolated hunt for RNA. Since mid-September, three large Western firms have paid for Chinese-origin assets in obesity, blood cancer and autoimmunity. The cash up front is real. Most of the headline value still sits in milestones that may never be paid.

THE THREE CHINA DEALS

Hengrui Pharma said on September 29 that Novo Nordisk licensed HRS-1596, a Phase I-ready once-weekly oral GLP-1/GIP agonist, for obesity, type 2 diabetes and other metabolic disease. Novo gets exclusive rights to develop, make and sell the pill worldwide except the Chinese mainland, Hong Kong, Macao and Taiwan. The total potential value is up to $2.6 billion, including $300 million up front, plus royalties in the licensed territory. Hengrui already has Chinese clearance to start Phase 1 in weight management and type 2 diabetes. Closing is aimed at the fourth quarter of 2026, subject to U.S. Hart-Scott-Rodino review.

Frank Jiang, Hengrui’s executive vice president and chief strategy officer, said the pill could offer once-weekly oral dosing. Martin Holst Lange, Novo’s chief scientific officer, said the firm wants to raise the bar for convenience in a field it already sells into. The candidate has not been tested in people, so it will not change the Wegovy and Zepbound fight this year.

On September 15, GSK said it would buy global rights to a trispecific T cell-engager for multiple myeloma from privately held Chimagen Biosciences, with a total potential value of up to $750 million. The upfront fee was not disclosed. GSK plans Phase 1 in 2027. Hesham Abdullah, GSK’s senior vice president and global head of oncology, said the design aims at deeper responses and a cleaner safety profile than current T-cell engagers, which carry tough tolerability limits. Chimagen chief executive Zhenhao Zhou said the pact pairs the firm’s antibody platforms with GSK’s late-stage machine. GSK already holds Chimagen’s dual CD19/CD20 program CMG1A46, now in Phase 1. Multiple myeloma is the third most common blood cancer, with about 180,000 new cases a year. GSK cites forecasts that the U.S. T-cell engager market in that disease will exceed $10 billion by 2032.

AstraZeneca also moved on October 2 with Summit Therapeutics to test Datroway alongside ivonescimab, a bispecific antibody originated by China’s Akeso. The same week’s calendar is crowded on purpose.

Chinese Molecules Now Make Up One-Third of Pipelines

ING’s Asia Pharmaceuticals Report 2026, released June 15, put China at an estimated 33 percent of innovative molecules globally, up from 4 percent in 2014. That is the figure behind the deal flow, and it is no longer a rounding error.

WHAT ING COUNTED

• China’s share: About 33 percent of innovative molecules in global pipelines in 2026, up from 4 percent in 2014.
• First approvals: China’s share of first global approvals of new drugs rose from about 2 percent in 2015 to about 39 percent in 2024, beside about 41 percent for the United States.
• Asia’s weight: The region originates close to half of innovative molecules in global pipelines and about 90 percent of worldwide growth in new drug candidates.
• Capital: China took 75 percent of venture and private equity flowing into Asia Pacific biotech, ING said, after a decade of faster reviews, tax credits and state-backed clusters in Shanghai and Suzhou.

Diederik Stadig, ING’s senior economist for healthcare and technology, said Asia’s role is expanding from supplying the world to shaping what the world takes. ING also projects Asia will pass Europe by 2027 as the second-largest drug market after North America, as global sales reach $2.4 trillion by 2030. South Korea, in the same report, produced more than 1,300 candidates in three years, about 10 percent of the global total.

Beijing’s latest five-year industry plan sets a target that at least 25 percent of first-in-class drugs worldwide should be Chinese-origin by 2030. ING’s own line is blunter. The bank said the next Pfizer is likely to come from China, on the back of oncology, antibody-drug conjugates, bispecific antibodies, and cell and gene therapy.

Why Western Boards Keep Signing China Term Sheets

Boards are not shopping in Suzhou for the scenery. Evaluate, a pharmaceutical data firm, has put about $300 billion of branded sales at risk by 2030 as patents and exclusivity lapse. Merck’s Keytruda is the largest single line in that stack. Evaluate forecasts about $32.7 billion of Keytruda sales in 2026, with core U.S. patent protection due in 2028. Novo’s Wegovy franchise faces generic pressure in the early 2030s. GSK has said it is rebuilding oncology ahead of losses on HIV medicines.

Internal discovery has not filled those holes on the timetable investors want. Chinese labs can run large early trials at lower cost, and a decade of review reform cut the backlog that used to keep Chinese molecules at home. The assets on offer now are not copycat pills. They are dual agonists, trispecific engagers and mRNA instructions for proteins the patient makes on site.

John Stanford, executive director of the policy group Incubate, cited $43 billion of licensing deals with Chinese companies in the first five months of 2026 alone. That pace is why a Phase I-ready weekly obesity pill can clear $300 million up front, and why an early mRNA engager can clear $575 million. The buyer is paying for optionality on a cliff, not for a drug that is already on a pharmacy shelf.

The Contracts Split Rights Three Ways

The term sheets do not all look like a fire sale of Chinese intellectual property. Each buyer took a different slice of the world, and that split will decide who collects the rent if a molecule works.

HOW THE RIGHTS WERE CUT

• Novo and Hengrui: Hengrui keeps the Chinese mainland, Hong Kong, Macao and Taiwan, and still earns royalties on Novo’s sales everywhere else.
• GSK and Chimagen: GSK takes full global rights to the myeloma program, so Chimagen’s upside is the undisclosed upfront fee plus milestones, not a home-market franchise.
• Novartis and Abogen: Novartis takes a worldwide license on ABO2203 and options on later RNA programs, with royalties if products sell.

Hengrui’s structure is the one Chinese boards will try to repeat. Keep the fastest-growing domestic market, take a large cash payment, and ride Western sales through royalties. GSK’s structure is a straight asset buy, useful when the seller is private and wants an exit. Abogen’s structure sells the lead shot and rents the factory that might make the next ones.

In every case the Western logo will be on the Phase 3 program and, if it works, on the U.S. and European label. The discovery file still starts in China. That is the transfer the headline values hide.

Washington Screens Vendors While Boards Buy Molecules

U.S. law is moving in the opposite direction of these term sheets, and not by accident. The BIOSECURE Act, enacted with the fiscal 2026 defense bill, bars federal agencies from contracting with designated biotechnology companies of concern and follows that ban into grant and loan money. It does not, on its face, stop a private license between Novartis and Abogen or Novo and Hengrui.

The Comprehensive Outbound Investment National Security Act built Treasury’s first statutory outbound screen, but left biotechnology off the list. Implementing rules are due in March 2027. On June 2, 2026, Reps. John Moolenaar and Debbie Dingell introduced the Biotech Investment National Security Act, which would add biotechnology to both the notifiable and prohibited technology lists. In February and again in May, Moolenaar urged Treasury Secretary Scott Bessent to treat China biotech licensing as a dependence risk.

On June 8, 2026, the Defense Department added WuXi AppTec, a major Chinese drug-development contractor, to its Section 1260H list of Chinese military companies. That listing does not automatically trigger a BIOSECURE ban, and WuXi later won a temporary court reprieve. Boards still read 1260H as a warning light on vendors, even when the molecule itself is the product they want.

The question is no longer whether Chinese pharma companies will reach global scale, but when and whether they will do so without relying on Western partners. While geopolitical scrutiny, including measures like the BIOSECURE Act, is unlikely to halt Western engagement with Chinese innovation, it could make cross-border partnerships more complex, selective and politically sensitive.

Stephen Farrelly, global lead for Pharma and Healthcare, ING

That is the bind. Security policy is still aimed at contract manufacturers and federal supply chains. The money is aimed at the molecules. Capital can treat Chinese labs as a rival in AI and a supplier in autoimmunity on the same day, because the patent clock does not wait for Congress to finish a list.

Western Discovery Shops Face a Crowded Door

Every dollar that goes to a Suzhou or Shanghai originator is a dollar that does not go to a Series B antibody shop in Boston or Cambridge as a first look. Large firms still buy Western biotech. They also now run a standing search in China, and the average check there has grown large enough to set the clearing price for early assets everywhere else.

The crowding is harshest for Western teams selling the same modalities China already makes in bulk: PD-1 combinations, antibody-drug conjugates, metabolic peptides, T-cell engagers. A U.S. founder with a bispecific and a Phase 1 slot is bidding against files that already have Chinese trial data and a lower cash need. Some Western startups have inverted the model and launched around in-licensed Chinese molecules, which only tightens the same loop.

Patients may still win if the drugs work, because a weekly oral dual agonist or an in-body T-cell engager is judged on endpoints, not on the city where the lead was synthesized. The open question is who owns the next label. ING’s Farrelly asked when Chinese firms will reach global scale without Western partners. The Abogen, Hengrui and Chimagen contracts still route U.S. and EU development through Novartis, Novo and GSK. The next round of five-year targets is written to make that routing optional.

The Abogen agreement is not closed. It still needs the clearances both sides flagged on October 2. Until those land, the $575 million is a term, not a wire, and the $7.8 billion remains a stack of milestones. The direction of the shopping is not in doubt.

Disclaimer: This article is news reporting and analysis of corporate licensing deals and industry data. It is for information only and is not investment advice, a recommendation to buy or sell any security, or medical advice about any drug, trial or treatment. Readers should consult a licensed financial adviser before making investment decisions and a qualified physician before making health decisions. Deal values, trial timelines, patent dates and pipeline shares reflect the company statements, ING figures and other sources cited here as of the dates on those documents and may change as closings, trials and regulations move.